160 related articles for article (PubMed ID: 36788189)
1. CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer.
Thalji SZ; Kamgar M; George B; Aldakkak M; Christians KK; Clarke CN; Erickson BA; Hall WA; Tolat PP; Smith ZL; Evans DB; Tsai S
Ann Surg Oncol; 2023 May; 30(5):3013-3021. PubMed ID: 36788189
[TBL] [Abstract][Full Text] [Related]
2. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.
Chun JW; Lee SH; Kim JS; Park N; Huh G; Cho IR; Paik WH; Ryu JK; Kim YT
BMC Cancer; 2021 May; 21(1):537. PubMed ID: 33975561
[TBL] [Abstract][Full Text] [Related]
3. Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis.
Chan KKW; Guo H; Cheng S; Beca JM; Redmond-Misner R; Isaranuwatchai W; Qiao L; Earle C; Berry SR; Biagi JJ; Welch S; Meyers BM; Mittmann N; Coburn N; Arias J; Schwartz D; Dai WF; Gavura S; McLeod R; Kennedy ED
Cancer Med; 2020 Jan; 9(1):160-169. PubMed ID: 31724340
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Kim S; Signorovitch JE; Yang H; Patterson-Lomba O; Xiang CQ; Ung B; Parisi M; Marshall JL
Adv Ther; 2018 Oct; 35(10):1564-1577. PubMed ID: 30209750
[TBL] [Abstract][Full Text] [Related]
5. Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
Lee JC; Woo SM; Shin DW; Kim J; Yang SY; Kim MJ; Kim JW; Kim JW; Lee WJ; Cha HS; Park P; Kim J; Hwang JH
Am J Clin Oncol; 2020 Sep; 43(9):654-659. PubMed ID: 32889836
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.
Franco F; Camara JC; Martín-Valadés JI; López-Alfonso A; Marrupe D; Gutiérrez-Abad D; Martínez-Amores B; León A; Juez I; Pérez M; Royuela A; Ruiz-Casado A
Clin Transl Oncol; 2021 Apr; 23(4):812-819. PubMed ID: 32857340
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Arima S; Kawahira M; Shimokawa M; Ido A; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Fukahori M; Makiyama A; Taguchi H; Honda T; Shibuki T; Mitsugi K; Nio K; Ide Y; Ureshino N; Mizuta T; Shirakawa T; Otsuka T
Pancreas; 2021 Aug; 50(7):957-964. PubMed ID: 34347735
[TBL] [Abstract][Full Text] [Related]
8. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer.
Ay S; Atcı MM; Arıkan R; Dülgar Ö; Özyükseler DT; Paksoy N; Doğan İ; Öztosun B; Taştekin D; Öven BB; Gümüş M
J Chemother; 2022 Nov; 34(7):465-471. PubMed ID: 35037592
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis.
Hayuka K; Okuyama H; Murakami A; Okita Y; Nishiuchi T; Okano K; Suzuki Y; Tsuji A
Chemotherapy; 2021; 66(3):58-64. PubMed ID: 34284397
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study.
Yang L; Su J; Wang W; Zhou F
World J Surg Oncol; 2023 Jan; 21(1):19. PubMed ID: 36691032
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
Tahara J; Shimizu K; Otsuka N; Akao J; Takayama Y; Tokushige K
Cancer Chemother Pharmacol; 2018 Aug; 82(2):245-250. PubMed ID: 29846765
[TBL] [Abstract][Full Text] [Related]
12. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
13. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study.
Ushida Y; Inoue Y; Oba A; Mie T; Ito H; Ono Y; Sato T; Ozaka M; Sasaki T; Saiura A; Sasahira N; Takahashi Y
Ann Surg Oncol; 2022 Aug; 29(8):5038-5050. PubMed ID: 35294658
[TBL] [Abstract][Full Text] [Related]
14. Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Ide Y; Otsuka T; Shimokawa M; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Arima S; Fukahori M; Makiyama A; Shinohara Y; Ueno S; Taguchi H; Honda T; Shibuki T; Nio K; Ureshino N; Mizuta T; Mitsugi K; Shirakawa T
Anticancer Res; 2023 Apr; 43(4):1817-1826. PubMed ID: 36974805
[TBL] [Abstract][Full Text] [Related]
15. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer.
Weniger M; Moir J; Damm M; Maggino L; Kordes M; Rosendahl J; Ceyhan GO; Schorn S;
Pancreatology; 2020 Sep; 20(6):1131-1138. PubMed ID: 32739267
[TBL] [Abstract][Full Text] [Related]
16. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
17. Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies.
Yamamoto KN; Nakamura A; Liu LL; Stein S; Tramontano AC; Kartoun U; Shimizu T; Inoue Y; Asakuma M; Haeno H; Kong CY; Uchiyama K; Gonen M; Hur C; Michor F
PLoS One; 2019; 14(4):e0215409. PubMed ID: 31026288
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel
Taguchi H; Otsuka T; Shimokawa M; Arima S; Hashimoto S; Ido A; Koga F; Ueda Y; Nakazawa J; Komori A; Otsu S; Fukahori M; Makiyama A; Honda T; Shibuki T; Mizuta T; Mitsugi K; Nio K; Ide Y; Ureshino N; Shirakawa T
Anticancer Res; 2021 Jul; 41(7):3573-3582. PubMed ID: 34230153
[TBL] [Abstract][Full Text] [Related]
19. Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer.
Kato A; Naitoh I; Naiki-Ito A; Hayashi K; Okumura F; Fujita Y; Sano H; Nishi Y; Miyabe K; Inoue T; Hirano A; Takada H; Yoshida M; Hori Y; Natsume M; Kato H; Takahashi S; Kataoka H
Pancreas; 2022 Apr; 51(4):372-379. PubMed ID: 35695793
[TBL] [Abstract][Full Text] [Related]
20. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).
Ozaka M; Nakachi K; Kobayashi S; Ohba A; Imaoka H; Terashima T; Ishii H; Mizusawa J; Katayama H; Kataoka T; Okusaka T; Ikeda M; Sasahira N; Miwa H; Mizukoshi E; Okano N; Mizuno N; Yamamoto T; Komatsu Y; Todaka A; Kamata K; Furukawa M; Fujimori N; Katanuma A; Takayama Y; Tsumura H; Fukuda H; Ueno M; Furuse J;
Eur J Cancer; 2023 Mar; 181():135-144. PubMed ID: 36652891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]